Exhibit (c)(14)

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Project Francis Conflicts Committee GP LLC Discussion Materials of the Board of Directors of Arkose May 1, 2018 PRIVATE AND CONFIDENTIAL. This document is being sent to you for your information only as an investment banking client of Goldman Sachs and should not be forwarded outside of your organization. This document has been prepared by the Investment Banking Division and is not a product of Goldman Sachs Global Investment Research. This document should not be used as a basis for trading in the securities or loans of the companies named herein or for any other investment decision. This document does not constitute an offer to sell the securities or loans of the companies named herein or a solicitation of proxies or votes and should not be construed as consisting of investment advice. Goldman Sachs does not provide accounting, tax, or legal advice.

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Disclaimer These materials have been prepared and are provided by Goldman Sachs on a confidential basis solely for the information and assistance of the Conflicts Committee of Board of Directors of Arkose GP LLC (the “Committee"), the general partner of Arkose GP LP (the "Company"), in connection with its consideration of the matters referred to herein. These materials and Goldman Sachs’ presentation relating to these materials (the “Confidential Information”) may not be disclosed to any third party or circulated or referred to publicly or used for or relied upon for any other purpose without the prior written consent of Goldman Sachs. The Confidential Information was not prepared with a view to public disclosure or to conform to any disclosure standards under any state, federal or international securities laws or other laws, rules or regulations, and Goldman Sachs does not take any responsibility for the use of the Confidential Information by persons other than those set forth above. Notwithstanding anything in this Confidential Information to the contrary, the Company may disclose to any person the US federal income and state income tax treatment and tax structure of any transaction described herein and all materials of any kind (including tax opinions and other tax analyses) that are provided to the Company relating to such tax treatment and tax structure, without Goldman Sachs imposing any limitation of any kind. The Confidential Information has been prepared by the Investment Banking Division of Goldman Sachs and is not a product of its research department. Goldman Sachs and its affiliates are engaged in advisory, underwriting and financing, principal investing, sales and trading, research, investment management and other financial and non-financial activities and services for various persons and entities. Goldman Sachs and its affiliates and employees, and funds or other entities they manage or in which they invest or have other economic interests or with which they co-invest, may at any time purchase, sell, hold or vote long or short positions and investments in securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments of the Company, any other party to any transaction and any of their respective affiliates or any currency or commodity that may be involved in any transaction. Goldman Sachs’ investment banking division maintains regular, ordinary course client service dialogues with clients and potential clients to review events, opportunities, and conditions in particular sectors and industries and, in that connection, Goldman Sachs may make reference to the Company, but Goldman Sachs will not disclose any confidential information received from the Company. The Confidential Information has been prepared based on historical financial information, forecasts and other information obtained by Goldman Sachs from publicly available sources, the management of the Company or other sources (approved for our use by the Company in the case of information from management and non-public information). In preparing the Confidential Information, Goldman Sachs has relied upon and assumed, without assuming any responsibility for independent verification, the accuracy and completeness of all of the financial, legal, regulatory, tax, accounting and other information provided to, discussed with or reviewed by us, and Goldman Sachs does not assume any liability for any such information. Goldman Sachs does not provide accounting, tax, legal or regulatory advice. Goldman Sachs has not made an independent evaluation or appraisal of the assets and liabilities (including any contingent, derivative or other off-balance sheet assets and liabilities) of the Company or any other party to any transaction or any of their respective affiliates and has no obligation to evaluate the solvency of the Company or any other party to any transaction under any state or federal laws relating to bankruptcy, insolvency or similar matters. The analyses contained in the Confidential Information do not purport to be appraisals nor do they necessarily reflect the prices at which businesses or securities actually may be sold or purchased. Goldman Sachs’ role in any due diligence review is limited solely to performing such a review as it shall deem necessary to support its own advice and analysis and shall not be on behalf of the Company. Analyses based upon forecasts of future results are not necessarily indicative of actual future results, which may be significantly more or less favorable than suggested by these analyses, and Goldman Sachs does not assume responsibility if future results are materially different from those forecast. The Confidential Information does not address the underlying business decision of the Company to engage in any transaction, or the relative merits of any transaction or strategic alternative referred to herein as compared to any other transaction or alternative that may be available to the Company. The Confidential Information is necessarily based on economic, monetary, market and other conditions as in effect on, and the information made available to Goldman Sachs as of, the date of such Confidential Information and Goldman Sachs assumes no responsibility for updating or revising the Confidential Information based on circumstances, developments or events occurring after such date. The Confidential Information does not constitute any opinion, nor does the Confidential Information constitute a recommendation to the Committee, any security holder of the Company or any other person as to how to vote or act with respect to any transaction or any other matter. The Confidential Information, including this disclaimer, is subject to, and governed by, any written agreement between the Company and the Committee, on the one hand, and Goldman Sachs, on the other hand. 1

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Comparison of Series B Value Status Quo GP Share Count ($ in millions) Series B Value Calculation of Series B Value Management Presentation Conversion Mechanism Methodology 2026E Series B Dist. (/) Series B Take (+) Annual Series B Threshold $ 48 6.0 % $ 30 (-) Series B Dist. $(48) (-) G&A (-) Taxes (25.3%) (2) (199) DCF Coverage Ratio Total 2016E GP Dist. (Series A Dist.) Assumed Terminal Yield 1.0 x $ 586 10.0 % (-) $2.0bn Threshold (2,000) 2026E Series B Dist. Assumed Terminal Yield $ 48 10.0 % (x) Series B Take 6.0 % (/) 2026E Discount Factor (/) 2026E Discount Factor 1.77 1.84 Discounted Distributions Discounted Distributions $ 183 $ 183 Management @ 7.25% Discount Rate 10% Terminal Yield Comparative Calculation @ 7.25% Discount Rate 10% Terminal Yield PV of Distributions PV of Terminal Value Source: Arkose Projections, Wall Street research and Bloomberg market data as of 27-Apr-2018 Note: Series B value calculated as the PV of distributions through 2026 and the TV at year end 2026. Executive Summary 2 Management calculates terminal value using mid-year convention resulting a in discount factor of 1.77. Conversion Mechanism Methodology calculates terminal value using a year-end methodology resulting in a discount factor of 1.84 Total Series B Value$ 309 Total Series B Value$ 453 Series B Discounted TV$ 126 Series B Discounted TV$ 270 Implied 2026 Series B Value$ 232 Implied 2026 Series B Value$ 479 Equity Value Subject to Series B$ 3,861 Implied GP Market Cap in 2026$ 5,861 Total Implied 2026E GP DCF$ 586 Implied GP Cash Flow$ 787 $453 $309 $270 $126 $183 $183 Implied CF to IDR Holding LLC$ 835 Management used an implied terminal yield methodology on Series B cash flows instead of the conversion mechanic as per the agreement

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Cost of Equity Comparison Calculation Management Identified Comps GP Midstream Average EQGP TEGP WGP Levered Beta 1.22 1.26 0.95 0.96 1.02 0.87 Risk Free Rate 2.96 % 2.96 % 2.96 % 2.96 % 2.96 % 2.96 % Equity Risk Premium (Duff & Phelps) 6.90 6.90 6.90 6.90 6.90 6.90 Comparative Calculation (with KPMG Equity Risk Premium) Management Identified Comps GP Midstream Average EQGP TEGP WGP Levered Beta 1.22 1.26 0.95 0.96 1.02 0.87 Risk Free Rate 2.96 % 2.96 % 2.96 % 2.96 % 2.96 % 2.96 % Equity Risk Premium (KPMG) 5.75 5.75 % 5.75 % 5.75 % 5.75 % 5.75 % Growth Adjusted Yield 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E 2026E GP Share Price Distribution $ 17.31 0.54 $ 17.31 0.89 $ 17.31 1.34 $ 17.31 1.74 $ 17.31 2.22 $ 17.31 2.51 $ 17.31 2.83 $ 17.31 3.07 $ 17.31 3.15 Adjusted Equity Yield 3.1 % 5.1 % 7.7 % 10.1 % 12.8 % 14.5 % 16.3 % 17.8 % 18.2 % Source: Arkose Management Series B Valuation Analysis (26-Apr-2018), Axioma, Duff & Phelps and Bloomberg market data as of 27-Apr-2018 Note: Two year historical Levered Beta per Axioma. Risk Free Rate represents yield of 30-year U.S. Government Treasury Notes with 20 years remaining life. Equity Risk Premium per Duff & Phelps. Executive Summary 3 7 Yr Equity Yield Avg. 10.0 % 9 Yr Equity Yield Avg. 11.7 Cost of Equity 10.0 % 10.2 % 8.4 % 8.5 % 8.8 % 8.0 % Cost of Equity 11.4 % 11.6 % 9.5 % 9.6 % 10.0 % 9.0 %

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Comparison of Series Value Status Quo GP Share Count B Distribution on Terminal 11.5% Discount Rate 10.0% Discount Rate $299 $273 Comparative Calculation 8% Terminal Yield Comparative Calculation 10% Terminal Yield Comparative Calculation 12% Terminal Yield Comparative Calculation 8% Terminal Yield Comparative Calculation 10% Terminal Yield Comparative Calculation 12% Terminal Yield PV of Distributions PV of Terminal Value PV of Distributions PV of Terminal Value Status Quo Corresponding GP Share Price $25.56 $22.52 $20.50 $28.18 $24.76 $22.49 Source: Arkose Projections, Wall Street research and Bloomberg market data as of 27-Apr-2018 Note: Series B value calculated as the PV of distributions through 2026 and the TV at year end 2026. Executive Summary 4 $123 $239 $89 $217 $67 $150 $150 $150 $139 $261 $101 $236 $75 $161 $161 $161

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Illustrative Analysis at Various Implied GP Share Prices Pro Forma Arkose GP + Midstream | Illustrative 1.6x Exchange Ratio Median Analyst Implied Total Equity Value Market Implied Total Equity Value¹ 5% Equity Upside to Market Value² 10% Equity Upside to Market Value² 15% Equity Upside to Market Value² 20% Equity Upside to Market Value² 30% Equity Upside to Market Value² Premium to NBLX % Uplift from Current Equity Value $ Uplift from Current Equity Value Current GP Shares (+) Pro Forma Midstream Units (at 1.6 x Ech. Ratio) (+) Shares Issued to Series B Units @ 3.0 % PF Interest NA $ 0 186 301 11 5 % $417 186 301 12 10 % $875 186 301 12 15 % $1,374 186 301 12 20 % $1,916 186 301 12 30 % $2,999 186 301 12 42 % $4,237 186 301 12 62 % $7,355 186 301 13 Total Pro Forma Shares Outstanding 498 498 499 499 499 499 499 500 % Change From Current Share Price (3)% 1 % 6 % 11 % 16 % 25 % 37 % 56 % 2.5 % 9.4 9.6 9.7 9.8 9.9 10.1 10.3 10.6 3.0 11.4 11.5 11.7 11.8 12.0 12.2 12.5 12.8 3.5 13.3 13.5 13.7 13.9 14.0 14.3 14.6 15.0 4.0 15.3 15.5 15.7 15.9 16.1 16.4 16.8 17.2 4.5 17.2 17.5 17.8 18.0 18.2 18.5 18.9 19.4 2.5 % $ 158 $ 169 $ 179 $ 189 $ 200 $ 221 $ 247 $ 287 190 202 215 227 240 265 296 345 3.0 3.5 222 236 251 265 280 309 345 402 4.0 253 270 287 303 320 353 394 460 4.5 285 304 322 341 360 397 444 517 Source: Arkose Projections, Wall Street research and Bloomberg market data as of 27-Apr-2018 Note: Pro forma analysis assumes 1.1x coverage ratio in 2018 and 2019-2022 coverage ratios held constant to current standalone forecasts. 1 Assumes current market price and series B converts into SQ GP market cap. 2 Assumes pro forma GP trades at a 5%, 10%, 15%, 20% and 30% premium to current market valuation assuming Series B units convert into SQ GP market cap. Executive Summary 5 B Interest (Based on Pro Forma Series B Take Implied Value of Series Implied GP Share Price) Current Prices GP: $17.31 Midstream: $26.82 Pro Forma Series B Take Implied # of GP Share Issued for Series B Implied GP Share Price $ 16.72 $ 17.55 $ 18.38 $ 19.21 $ 20.04 $ 21.69 $ 23.75 $ 27.01 Implied Pro Forma Equity Value $ 8,330 $ 8,747 $ 9,163 $ 9,580 $ 9,996 $ 10,829 $ 11,861 $ 13,496

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Illustrative Analysis at Various Implied GP Share Prices (con’t) Pro Forma Arkose GP + Midstream | Illustrative 1.8x Exchange Ratio Median Analyst Implied Total Equity Value Market Implied Total Equity Value¹ 5% Equity Upside to Market Value² 10% Equity Upside to Market Value² 15% Equity Upside to Market Value² 20% Equity Upside to Market Value² 30% Equity Upside to Market Value² Premium to NBLX % Uplift from Current Equity Value $ Uplift from Current Equity Value Current GP Shares (+) Pro Forma Midstream Units (at 1.8 x Ech. Ratio) (+) Shares Issued to Series B Units @ 3.0 % PF Interest NA $ 0 186 338 12 5 % $417 186 338 12 10 % $875 186 338 13 15 % $1,374 186 338 13 20 % $1,916 186 338 13 30 % $2,999 186 338 13 42 % $4,237 186 338 13 62 % $7,355 186 338 14 Total Pro Forma Shares Outstanding 537 537 537 537 537 538 538 538 % Change From Current Share Price (10)% (6)% (1)% 3 % 7 % 16 % 27 % 45 % 2.5 % 10.2 10.3 10.5 10.6 10.7 10.9 11.1 11.4 3.0 12.2 12.4 12.6 12.8 12.9 13.2 13.4 13.8 3.5 14.3 14.6 14.8 14.9 15.1 15.4 15.7 16.1 4.0 16.4 16.7 16.9 17.1 17.3 17.7 18.0 18.5 4.5 18.6 18.9 19.1 19.4 19.6 20.0 20.4 20.9 2.5 % $ 158 $ 169 $ 179 $ 189 $ 200 $ 221 $ 247 $ 287 190 202 215 227 240 265 296 345 3.0 3.5 222 236 251 265 280 309 345 402 4.0 253 270 287 303 320 353 394 460 4.5 285 304 322 341 360 397 444 517 Source: Arkose Projections, Wall Street research and Bloomberg market data as of 27-Apr-2018 Note: Pro forma analysis assumes 1.1x coverage ratio in 2018 and 2019-2022 coverage ratios held constant to current standalone forecasts. 1 Assumes current market price and series B converts into SQ GP market cap. 2 Assumes pro forma GP trades at a 5%, 10%, 15%, 20% and 30% premium to current market valuation assuming Series B units convert into SQ GP market cap. Executive Summary 6 B Interest (Based on Pro Forma Series B Take Implied Value of Series Implied GP Share Price) Current Prices GP: $17.31 Midstream: $26.82 Pro Forma Series B Take Implied # of GP Share Issued for Series B Implied GP Share Price $ 15.52 $ 16.29 $ 17.06 $ 17.83 $ 18.60 $ 20.14 $ 22.05 $ 25.07 Implied Pro Forma Equity Value $ 8,330 $ 8,747 $ 9,163 $ 9,580 $ 9,996 $ 10,829 $ 11,861 $ 13,496

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Appendix A: Additional Reference Materials

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Illustrative Conversion Calculation For Series B Units of Arkose IDR LLC Management Case Conversion into Pro Forma Market Cap Series B Conversion Into Status Quo GP Shares 20 Trading-Day GP VWAP (Current) (x) Common Shares Outstanding $ 16.25 186 GP Share Price1 (x) Common Shares Outstanding $ 19.63 487 GP Market Cap (-) $2.0bn Threshold $ 3,026 (2,000) Pro Forma GP Market Cap (-) $2.0bn Threshold $ 9,559 (2,000) (x) Series B Take 6.0 % (x) Series B Take (Illustrative Assumption) 3.0 % (x) Units Outstanding (x) Percent Vested 100 % 100 % (x) Units Outstanding (x) Percent Vested 100 % 100 % (/) Vested Units Outstanding 98.6 (/) Vested Units Outstanding 98.6 (x) Vested Units Redeemed (/) 20 Day GP VWAP (Current) 98.6 $ 16.25 (x) Vested Units Redeemed (/) 20 Day GP VWAP 98.6 $ 19.63 Pro Forma Share Count (Illustrative) Common GP Shares Outstanding Midstream Units Outstanding Exchange Ratio (Illustrative) Shares Issued to Midstream 186.2 188.0 1.60 x 300.8 GP Buys Midstream Transaction Source: GP 424 B4 filing dated 05-May-2017 and GP IDR Holdings LLC Limited Liability Company Agreement dated 31-Dec-2016; Bloomberg market data as of 27-Apr-2018 1 $19.63 20-trading day VWAP actual observed 20-day VWAP for 1-Sep-2017 – 29-Sep-2017. Additional Reference Materials 8 Total Pro Forma Shares Outstanding487.0 Conversion - Common Shares Issued12 Conversion - Common Shares Issued 4 Per Vested B Unit Entitlement$ 2.30 Per Vested B Unit Entitlement $ 0.62 Total Entitlement$ 227 Total Entitlement $ 62 Memo: illustrative assumption Class B Share$ 227 Class B Share $ 62 Equity Value Subject to Series B Take$ 7,559 Equity Value Subject to Series B Take $ 1,026

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Illustrative Implied Series B Value Dividend Discount Model Through Series B Redemption in 2026 | ($ in millions) Management Case Replication Status Quo Series B Dividend Discount Model Management Forecast Illustrative Extension of Projections 2018E1 2019E 2020E 2021E 2022E 2023E 2024E 2025E 2026E Midstream LP DPU Midstream LP DPU Y.o.Y. Growth Discount Period | Distributions Discount Factor | Distributions Discount Period | TV Discount Factor | TV GP DPS Y.o.Y. Growth Terminal Yield $ 1.33 $ 2.21 29 % 1.25 0.92 1.75 0.88 $ 0.89 107 % $ 2.85 29 % 2.25 0.85 2.75 0.82 $ 1.34 51 % $ 3.42 20 % 3.25 0.80 3.75 0.77 $ 1.74 30 % $ 4.10 20 % 4.25 0.74 4.75 0.72 $ 2.22 28 % $ 4.51 10 % 5.25 0.69 5.75 0.67 $ 2.51 13 % $ 4.96 10 % 6.25 0.65 6.75 0.62 $ 2.83 13 % $ 5.31 7 % 7.25 0.60 7.75 0.58 $ 3.07 9 % $ 5.41 2 % 8.25 0.56 8.75 0.54 $ 3.15 2 % 10.0 % 0.38 0.97 0.88 0.94 $ 0.43 Implied Future Market Cap Discount Rate $ 5,861 7.3 % Series B Cash Flows Memo: MGMT Series B CF Y.o.Y. Growth $ 2 2 $ 9 9 325 % $ 23 23 165 % $ 25 25 9 % $ 34 34 37 % $ 38 38 14 % $ 43 43 13 % $ 47 47 9 % $ 48 48 3 % Implied Shares Issued to Series B 7.4 Source: Arkose Projections, Wall Street research and Bloomberg market data as of 27-Apr-2018 Note: Assumes transaction date of 1-Jan-2018. Assumes mid-year convention starting Q2 2018. 1 2018E adjusted for Q1 distributions paid. Additional Reference Materials 9 Implied PV of Distributions$ 183 Implied PV of Terminal Value126 Implied Series B Value309 Discounted Distributions$ 2$ 8$ 19$ 20$ 25$ 26$ 28$ 28$ 27 Discounted Terminal Value126 Terminal Value Based on DDM-Implied Future GP Market Cap$ 232 Implied GP Share Price$29.65 Discounted Distributions$ 0.42$ 0.81$ 1.14$ 1.39$ 1.65$ 1.74$ 1.83$ 1.85$ 1.77 Discounted Terminal Value17.06 Terminal Value$ 31.48 GP Shares outstanding: 186

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Illustrative Implied Series B Value (Cont’d) Series B & GP Dividend Discount Model | ($ in millions) PV of Distributions PV of Terminal Value Total Value 8.0 % 10.0 % 12.0 % 8.0 % 10.0 % 12.0 % 8.0 % 10.0 % 12.0 % 7.25 % $ 126 $ 126 $ 94 $ 309 $ 309 $ 277 9.00 150 109 81 319 277 250 10.00 139 101 75 299 261 236 11.50 123 89 67 273 239 217 12.50 114 83 62 257 226 205 DDM Implied GP Share Price 8.0 % 10.0 % 12.0 % 7.25 % 9.00 10.00 11.50 12.50 Source: Arkose Projections, Wall Street research and Bloomberg market data as of 27-Apr-2018 Additional Reference Materials 10 $ 33.92$ 29.65$ 26.81 30.1226.4223.95 28.1824.7622.49 25.5622.5220.50 23.9821.1719.30 Cost of Equity Corresponding GP Illustrative Implied Terminal Yield $ 183$ 183$ 183 168168168 161161161 150150150 143143143 Cost of Equity Series B Illustrative Implied Terminal Yield Illustrative Implied Terminal Yield Illustrative Implied Terminal Yield

GRAPHIC

 

PRELIMINARY CONFIDENTIAL DRAFT – FOR DISCUSSION PURPOSES ONLY Reconciliation from Series B Distributions to GP DPS ($ in millions) | Management Case Replication Reconciliation from Series B Distributions to GP DPS 2018E 2019E 2020E 2021E 2022E 2023E 2024E 2025E 2026E Series B Dist Payable Incremental Series B Dist Declared $ 2 5 $ 9 4 $ 23 (3) $ 25 1 $ 34 0 $ 38 0 $ 43 0 $ 47 0 $ 48 0 Total Series B Value $ 7 $ 12 $ 20 $ 26 $ 34 $ 38 $ 43 $ 47 $ 48 (/) Series B Take (+) Annual Series B Threshold 6.0 % $ 30 6.0 % $ 30 6.0 % $ 30 6.0 % $ 30 6.0 % $ 30 6.0 % $ 30 6.0 % $ 30 6.0 % $ 30 6.0 % $ 30 (-) Series B Dist. (2) (9) (23) (25) (34) (38) (43) (47) (48) (-) G&A (-) Taxes (2) (34) (2) (56) (2) (85) (2) (110) (2) (140) (2) (158) (2) (179) (2) (194) (2) (199) GP Shares Outstanding 186 186 186 186 186 186 186 186 186 Source: Arkose Projections, Wall Street research and Bloomberg market data as of 27-Apr-2018 Additional Reference Materials 11 Implied GP DPS$ 0.56$ 0.91$ 1.32$ 1.75$ 2.22$ 2.51$ 2.83$ 3.07$ 3.15 Total Implied 2026E GP DCF$ 105$ 169$ 246$ 326$ 413$ 467$ 527$ 572$ 586 Implied GP Cash Flow$ 141$ 227$ 333$ 437$ 556$ 628$ 707$ 768$ 787 Implied CF to IDR Holding LLC$ 143$ 236$ 355$ 462$ 589$ 666$ 750$ 815$ 835

GRAPHIC